Edition:
United Kingdom

People: BioXcel Therapeutics Inc (BTAI.OQ)

BTAI.OQ on NASDAQ Stock Exchange Capital Market

9.12USD
22 Aug 2019
Change (% chg)

-- (--)
Prev Close
$9.12
Open
--
Day's High
--
Day's Low
--
Volume
--
Avg. Vol
13,324
52-wk High
$11.94
52-wk Low
$2.41

Yocca, Frank 

Dr. Frank D. Yocca, Ph.D. is Chief Scientific Officer of the Company. From April 2015 to April 2017, he was Senior Vice President, CNS R&D of BioXcel. From 2005 to 2015, Dr. Yocca held multiple leadership roles at AstraZeneca plc, including Vice President, Strategy and Externalization, Neuroscience Virtual Innovative Medicine Unit (iMed) (2011-2015), Vice President and Head, Strategy Unit, CNS and Pain Innovative Medicine Unit (iMed) (2010 to 2011) and Vice President and Head, CNS Pain Discovery (2005 to 2010). Prior to this he was Executive Director at the Bristol Myers Squibb Pharmaceutical Research Institute from 1984 to 2004 where he served concurrent leadership responsibilities within the Neuroscience Clinical Group for Early and Late Clinical Development Studies. Prior to this Dr. Yocca served as Executive Director, Neuroscience Discovery from 1997 to 2003, where he was a collaborator in the development and implementation of corporate strategic plans and leader for the Neuroscience Biology Department in the discovery of psychiatry and Alzheimer's clinical candidates. He was a core member of the Abilify Product Development and Commercialization Team from 1999 to 2002 and a core member of the Early and Late Discovery and Development Teams from 1984 to 2001. Dr. Yocca holds a B.S. in biochemistry from Manhattan College and an M.S. in pharmacology and a Ph.D. in neuropharmacology for St. John's University.

Basic Compensation

Total Annual Compensation, USD 168,000
Restricted Stock Award, USD --
Long-Term Incentive Plans, USD --
All Other, USD 41,999
Fiscal Year Total, USD 209,999

Options Compensation

  Quantity Market Value
Exercisable -- --
Unexercisable -- --
Exercised -- --